MannKind (MNKD) and its Indian partner Cipla said Wednesday that India's Central Drugs Standard Control Organization has approved Afrezza inhalation powder for adults with diabetes.
MannKind expects to ship Afrezza to Cipla by the end of 2025, the companies said.
Under an exclusive marketing and distribution agreement for Afrezza, Cipla was responsible for obtaining regulatory approvals as well as marketing and sales of Afrezza in India, while MannKind supplies the product to Cipla, according to a joint statement.
Afrezza is approved in the US and Brazil, the companies added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。